Second generation monoclonal antibodies having binding specificity to TAG-72 and human carcinomas and methods for employing the same
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsJeffrey Schlom, David Colcher
Life of this patent
Estimating the term…
Abstract
The present invention relates to second generation monoclonal antibodies having binding specificity to a tumor associated glycoprotein having an approximate molecular weight of >10.sup.6 d ("TAG-72") and human carcinomas and methods for employing the same. Hybridomas producing such antibodies have been prepared.
Claims44
A second generation monoclonal antibody, an immunoreactive fragment or an antigen binding recombinant thereof, which specifically binds both TAG-72 and LS174T cell line antigen but which does not substantially bind normal adult human tissues, wherein said monoclonal antibody has a binding affinity of greater than 3.times.10.sup.9 M.sup.-1 for TAG-72, and wherein said monoclonal antibody is CC49 (ATCC CRL 9459) or CC83 (ATCC CRL 9453) or specifically binds to an epitope specifically bound by CC49 or CC83.
A hybridoma producing a second generation monoclonal antibody which specifically binds both TAG-72 and LS174T antigens but which does not substantially bind normal adult human tissues, wherein said monoclonal antibody has a binding affinity of greater than 3.times.10.sup.9 M.sup.-1 for TAG-72, and wherein said monoclonal antibody is CC49 (ATCC CRL 9459) or CC83 (ATCC CRL 9453) or specifically binds to an epitope specifically bound by CC49 or CC83.
A second generation monoclonal antibody, an immunoreactive fragment or an antigen binding recombinant thereof, which specifically binds both TAG-72 and LS174T cell line antigen but which does not substantially bind normal adult human tissues, wherein said monoclonal antibody has a binding affinity of greater than 3.times.10.sup.9 M.sup.-1 for TAG-72, wherein said monoclonal antibody is CC 46 (ATCC CRL 9458), CC 92 (ATCC CRL 9454), CC 30 (ATCC CRL 9457), CC 11 (ATCC CRL 9455), CC 15 (ATCC CRL 9460), or MATAG 12 (ATCC CRL 9456), or specifically binds to an epitope specifically bound by CC 46, CC 92, CC 30, CC 11, CC 15, or MATAG 12.
A hybridoma producing a second generation monoclonal antibody which specifically binds both TAG-72 and LS174T antigens but which does not substantially bind normal adult human tissues, wherein said monoclonal antibody has a banding affinity of greater than 3.times.10.sup.9 M.sup.-1 for TAG-79, and wherein said monoclonal antibody is CC 46 (ATCC CRL 9458), CC 92 (ATCC CRL 9454), CC 30 (ATCC CRL 9457), CC 11 (ATCC CRL 9455), CC 15 (ATCC CRL 9460), or MATAG 12 (ATCC CRL 9456), or specifically binds to an epitope specifically bound by CC 46, CC 92, CC 30, CC 11, CC 15 or MATAG 12.
Dependencies are inferred from the claim text.